SCHEMBL2964378

SCHEMBL2964378

CC(=O)Nc1ccc(Sc2ccc(C)cc2Nc2ccnc3nc(C(F)(F)F)ccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.41
AURKB Q96GD4 2/20 0.39
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
CDK1 P06493 1/20 0.39
CDK2 P24941 1/20 0.39
FLT4 P35916 1/20 0.39
FLT3 P36888 1/20 0.39
FRK P42685 1/20 0.39
CDK8 P49336 1/20 0.39
CSNK2A1 P68400 1/20 0.39
CDK5 Q00535 1/20 0.39
ACVR1 Q04771 1/20 0.39
MST1R Q04912 1/20 0.39
STK3 Q13188 1/20 0.39
PTK6 Q13882 1/20 0.39
PIM3 Q86V86 1/20 0.39
MINK1 Q8N4C8 1/20 0.39
HIPK4 Q8NE63 1/20 0.39
PBK Q96KB5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023477 0.88 AURKA (0.41) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2016780 0.86 AURKA (0.40) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2961423 0.86 AURKA (0.40) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2960125 0.85 TRPV1 (0.40) SYKAURKBPRKD3PRKCGCDK1
SCHEMBL2961153 0.85 SREBF2 (0.44) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2957108 0.85 AURKA (0.43) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2969920 0.84 BLM (0.41) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2960267 0.84 BRAF (0.42) AURKBAURKAKDM4EALDH1A1HPGD
SCHEMBL2018147 0.84 AURKA (0.39) AURKBAURKAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2963009 0.84 MEN1 (0.39) SYKAURKBPRKD3PRKCGCDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SYK 4335/4885AURKB 2041/4885PRKD3 4590/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 SYK 4335/4885AURKB 2041/4885PRKD3 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.